Truvic Medical, Inc., a wholly-owned subsidiary of Imperative Care, Inc., today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Prodigy Thrombectomy System, designed for the treatment of peripheral vascular thrombus.

“We are excited to receive FDA clearance for our first thrombectomy system. We look forward to working with experts in the field to translate Prodigy’s novel design elements and features into superb clinical outcomes,” said Mike Buck, CEO of Truvic. “This represents our first regulatory milestone as part of our strategy to advance multiple programs designed to meet patients’ needs and bring more innovative technologies to the market, faster.”

“Imperative Care and Truvic share a culture of innovation and intense commitment to the needs of patients. I am pleased that these common values continue to help propel our development programs towards elevation of patient care,” said Fred Khosravi, Chairman and CEO of Imperative Care.

Source: Company Press Release